These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23433442)
41. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis. Kwon YJ; Kim HJ; Kim WG Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917 [TBL] [Abstract][Full Text] [Related]
42. Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712210 [TBL] [Abstract][Full Text] [Related]
43. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Thabit AK; Nicolau DP; Kuti JL Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306 [TBL] [Abstract][Full Text] [Related]
44. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Housman ST; Sutherland CA; Nicolau DP Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866 [TBL] [Abstract][Full Text] [Related]
45. Antimicrobial activity of gallium maltolate against Staphylococcus aureus and methicillin-resistant S. aureus and Staphylococcus pseudintermedius: An in vitro study. Arnold CE; Bordin A; Lawhon SD; Libal MC; Bernstein LR; Cohen ND Vet Microbiol; 2012 Mar; 155(2-4):389-94. PubMed ID: 21963417 [TBL] [Abstract][Full Text] [Related]
46. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547 [TBL] [Abstract][Full Text] [Related]
47. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Vidaillac C; Leonard SN; Rybak MJ Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009 [TBL] [Abstract][Full Text] [Related]
48. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007 [TBL] [Abstract][Full Text] [Related]
49. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Kebriaei R; Rice SA; Stamper KC; Rybak MJ Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436 [TBL] [Abstract][Full Text] [Related]
50. Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus. Herrera M; Mobilia L; Posse G; Limansky A; Ballerini V; Bantar C Curr Clin Pharmacol; 2013 Nov; 8(4):332-9. PubMed ID: 23590512 [TBL] [Abstract][Full Text] [Related]
51. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Leonard SN; Supple ME; Gandhi RG; Patel MD Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527 [TBL] [Abstract][Full Text] [Related]
52. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. Sader HS; Farrell DJ; Flamm RK; Jones RN Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170 [TBL] [Abstract][Full Text] [Related]
53. Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036691 [TBL] [Abstract][Full Text] [Related]
54. Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens. He Y; Tian J; Chen X; Sun W; Zhu H; Li Q; Lei L; Yao G; Xue Y; Wang J; Li H; Zhang Y Sci Rep; 2016 Apr; 6():24291. PubMed ID: 27063778 [TBL] [Abstract][Full Text] [Related]
55. Discovery of a novel and potent class of FabI-directed antibacterial agents. Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833 [TBL] [Abstract][Full Text] [Related]
56. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model. Hirai J; Hagihara M; Kato H; Sakanashi D; Nishiyama N; Koizumi Y; Yamagishi Y; Suematsu H; Hanaki H; Mikamo H J Infect Chemother; 2016 Jun; 22(6):387-94. PubMed ID: 27029221 [TBL] [Abstract][Full Text] [Related]
57. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804 [TBL] [Abstract][Full Text] [Related]
58. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263 [TBL] [Abstract][Full Text] [Related]